STOCK TITAN

AtaiBeckley Inc. (ATAI) CMO sells shares after exercising stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AtaiBeckley Inc.’s Chief Medical Officer, Craig Kevin James, reported an option exercise-and-sale transaction in company stock. On June 25, 2026, he exercised stock options covering 42,579 shares of common stock at strike prices of $1.18 and $1.50 per share and sold 42,579 shares in open-market transactions at a weighted average price of $4.51 per share. The filing states these option exercises and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025. After the transactions, he held 8,437 shares of common stock directly and continued to hold stock options, including 28,608 options at an exercise price of $1.18 expiring on March 14, 2033 and 673,808 options at an exercise price of $1.50 expiring on March 3, 2035.

Positive

  • None.

Negative

  • None.
Insider Craig Kevin James
Role Chief Medical Officer
Sold 42,579 shs ($192K)
Type Security Shares Price Value
Exercise Stock Option 33,051 $0.00 --
Exercise Stock Option 9,528 $0.00 --
Exercise Common Stock 33,051 $1.50 $50K
Exercise Common Stock 9,528 $1.18 $11K
Sale Common Stock 42,579 $4.51 $192K
Holdings After Transaction: Stock Option — 673,808 shares (Direct, null); Common Stock — 41,488 shares (Direct, null)
Footnotes (1)
  1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.50 to $4.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
Shares sold 42,579 shares Common stock sold on June 25, 2026
Weighted average sale price $4.51 per share Open-market transactions, prices $4.50–$4.54
Options exercised (shares) 42,579 shares Common stock acquired via option exercises
Strike price 1 $1.18 per share Stock option exercise price for 9,528 shares
Strike price 2 $1.50 per share Stock option exercise price for 33,051 shares
Common shares held after 8,437 shares Direct AtaiBeckley common stock ownership post-transaction
Remaining options at $1.18 28,608 options Exercise price $1.18, expiration March 14, 2033
Remaining options at $1.50 673,808 options Exercise price $1.50, expiration March 3, 2035
Rule 10b5-1 trading plan financial
"The option exercises and sales ... were effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. The securities were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option financial
"The stock option vested as to 25% of the underlying shares on January 1, 2026..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
substantially equal monthly installments financial
"with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter."
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Craig Kevin James

(Last)(First)(Middle)
C/O ATAI LIFE SCIENCES US, INC.
C/O INDUSTRIOUS NYC, 250 WEST 34TH ST.

(Street)
NEW YORK NEW YORK 10119

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AtaiBeckley Inc. [ ATAI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/25/2026M(1)33,051A$1.541,488D
Common Stock06/25/2026M(1)9,528A$1.1851,016D
Common Stock06/25/2026S(2)42,579D$4.518,437D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$1.506/25/2026M(1)33,051 (3)03/03/2035Common Stock33,051$0673,808D
Stock Option$1.1806/25/2026M(1)9,528 (4)03/14/2033Common Stock9,528$028,608D
Explanation of Responses:
1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
2. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.50 to $4.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
3. The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
4. The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
/s/ Ryan Barrett, as attorney in fact06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did AtaiBeckley (ATAI) report for Craig Kevin James?

AtaiBeckley’s Chief Medical Officer, Craig Kevin James, exercised stock options for 42,579 common shares and sold 42,579 shares in open-market transactions. These moves combined an option exercise with an immediate share sale, typical for converting option value into cash.

At what prices did the AtaiBeckley CMO sell and exercise ATAI shares?

Craig Kevin James sold 42,579 AtaiBeckley common shares at a weighted average price of $4.51 per share. He exercised options for those shares at strike prices of $1.18 and $1.50, locking in a spread between exercise cost and sale proceeds.

Was the AtaiBeckley CMO’s ATAI stock sale under a Rule 10b5-1 plan?

Yes. The filing states the option exercises and share sales were executed under a Rule 10b5-1 trading plan adopted on December 19, 2025. Such pre-arranged plans automate trades and reduce the significance of trade timing as a signal of insider sentiment.

How many AtaiBeckley (ATAI) shares does the CMO hold after these transactions?

Following the June 25, 2026 transactions, Craig Kevin James directly held 8,437 shares of AtaiBeckley common stock. This reflects his remaining direct equity stake after exercising options and selling 42,579 shares in the open market at a weighted average price of $4.51.

What stock options in AtaiBeckley (ATAI) does the CMO still own after exercising some?

After exercising part of his options, Craig Kevin James still holds 28,608 stock options with a $1.18 exercise price expiring March 14, 2033, and 673,808 options with a $1.50 exercise price expiring March 3, 2035. These positions maintain significant future equity exposure.

How many ATAI shares did the AtaiBeckley CMO sell in this Form 4 filing?

The Form 4 shows that Craig Kevin James sold 42,579 shares of AtaiBeckley common stock in open-market or private transactions. The weighted average sale price was reported as $4.51, with individual trades occurring between $4.50 and $4.54 per share.